57 pointsby andsoitis6 hours ago6 comments
  • bonsai_spool5 hours ago
    This is from February 2026 and notably there’s no way for the public to try out the model, nor is it published in a peer-reviewed journal
  • tusimi2 hours ago
    "In November 2024, preliminary results of CASP16 showed AlphaFold 3-based models did not significantly outperform older methods for predicting protein-ligand interactions. The top performing models in the CASP16 Pose Prediction for Pharma Targets section were ClusPro[13] and CoDock[14] utilizing AlphaFold 2 based predictions, human visual inspection, and manual adjustments.[15]

    In April 2025 Isomorphic Labs raised $600 Million in its first ever external funding round, led by Thrive Capital.[16][17]"

    https://en.wikipedia.org/wiki/Isomorphic_Labs

  • 13 minutes ago
    undefined
  • puttycat2 hours ago
    What technical advancement made this possible? The text is vague about this.
    • from_memory23 minutes ago
      there is a link to the white paper in the article.
  • ashwon135 hours ago
    Would like more details technically on their approach. Is it a neuro-symbolic approach, do they do something beyond just scaling, or some other architecture breakthrough, but alas drug discovery must remain proprietary. Thank gods for capitalism!
  • navvyeanand2 hours ago
    This is old news.